Pharmacokinetic interaction between fluvastatin and diltiazem in rats

Biopharmaceutics and Drug Disposition

Volumn 27, Issue 9, 2006, Pages 437-441

  Choi, Jun Shik ^a   Piao, Yong Ji ^a   Han, Hyo Kyung ^a  

^a Chosun University   (South Korea)

Author keywords

Diltiazem; Drug interaction; Fluvastatin; Pharmacokinetics; Rat

Indexed keywords

DILTIAZEM; FLUINDOSTATIN; CYTOCHROME P 450 3A4, RAT; CYTOCHROME P-450 3A4, RAT; CYTOCHROME P450; INDOLE DERIVATIVE; MONOUNSATURATED FATTY ACID;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENTIATION; MALE; NONHUMAN; RAT; ANIMAL; AREA UNDER THE CURVE; DRUG ANTAGONISM; DRUG INTERACTION; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; AREA UNDER CURVE; CYTOCHROME P-450 ENZYME SYSTEM; DILTIAZEM; DRUG INTERACTIONS; FATTY ACIDS, MONOUNSATURATED; INDOLES; MALE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 33846093023     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.521     Document Type: Article

References (19)

1. Chaffman M, Brogden RN. Diltiazem: a review of its pharmacological properties and therapeutic efficacy. Drugs 1985; 29: 387-454.
2. Weir MR. Diltiazem: ten years of clinical experience in the treatment of hypertension. J Clin Pharmacol 1995; 35: 220-232.
3. Gotto Jr AM. Risk factor modification: rationale for management of dyslipidemia. Am J Med 1998; 104: 6S-8S.
4. Wood D. Asymptomatic individuals - risk stratification in the prevention of coronary heart disease. Br Med Bull 2001; 59: 3-16.
5. Mousa O, Brater C, Sundblad KJ, Hall SD. The interaction of diltiazem with simvastatin. Clin Pharmacol Ther 2000; 67: 267-274.
6. Azie NE, Brater DC, Becker PA, Jones DR, Hall SD. The interaction of diltiazem with lovastatin and pravastatin. Clin Pharmacol Ther 1998; 64: 369-377.
7. Kanathur N, Mathai MG, Byrd Jr RP, Fields CL, Roy TM. Simvastatin-diltiazem drug interaction resulting in rhabdomyolysis and hepatitis. Tenn Med 2001; 94: 339-341.
8. Plosker GL, Wagstaff AJ. Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia. Drugs 1996; 51: 433-459.
9. Langtry HD, Markham A. Fluvastatin: a review of its use in lipid disorders. Drugs 1999; 57: 583-606.
10. Deslypere JP. Clinical implications of the biopharmaceutical properties of fluvastatin. Am J Cardiol 1994; 73: 12-17.
11. Fische V, Johanson L, Heitzl F. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metab Dispos 1999; 27: 410-416.
12. Cohen LH, van Leeuwen RE, van Thiel GC, van Pelt JF, Yap SH. Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos 2000; 21: 353-364.
13. Scripture CD, Pieper JA. Clinical pharmacokinetics of fluvastatin. Clin Pharmacokinet 2001; 40: 263-281.
14. Kivisto KT, Kantola T, Neuvonen PJ. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol 1998; 46: 49-53.
15. Yeung PKF, Mosher SJ, Quilliam MA, Montague TJ. Species comparison of pharmacokinetics and metabolism of diltiazem in humans, dogs, rabbits, and rats. Drug Metab Dispos 1990; 18: 1055-1059.
16. Goebel KJ, Kolle EU. High performance liquid chromatographic determination of diltiazem and four of its metabolites in plasma. J Chromatogr 1985; 345: 355-363.
17. Lee YH, Lee MH, Shim CK. Pharmacokinetics of diltiazem and deacetyldiltiazem in rats. Int J Pharm 1991; 76: 71-76.
18. Bogman K, Peyer AK, Torok M, Kusters E, Drewe J. HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br J Pharmacol 2001; 132: 1183-1192.
19. McDonnell CG, Shorten G, Van Pelt FN. Effect of atorvastatin and fluvastatin on the metabolism of midazolam by cytochrome P450 in vitro. Anaesthesia 2005; 60: 747-753.